Delix Therapeutics alternatives

Sage Therapeutics and Axsome Therapeutics both advance molecules that promote synaptic changes through GABA or glutamate pathways rather than Delix’s neuroplastogen scaffold, with Sage’s zuranolone already approved for postpartum depression.

Compass Pathways and MindMed run psilocybin and LSD-analog programs that also aim for rapid, lasting antidepressant effects via plasticity but retain hallucinogenic activity that Delix’s compounds are designed to avoid.

Johnson & Johnson’s Spravato (esketamine) and Biogen’s Alzheimer’s antibody portfolio are marketed products, while Delix remains preclinical; Sage’s zuranolone offers another approved fast-acting option.

Commercial-stage firms like J&J and Eli Lilly sell approved medicines through specialty pharmacies with established reimbursement, whereas Delix’s investor-funded model focuses on R&D milestones without current product revenue.

atai Life Sciences and Neurocrine Biosciences both pursue compounds intended for infrequent dosing with prolonged circuit-level effects, though their mechanisms target different receptors than Delix’s neuroplastogens.

Eli Lilly and Biogen operate broad neuroscience divisions with approved and late-stage assets for mood and neurodegenerative disorders, offering greater resources but less singular focus on structural neuroplasticity than Delix.